Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) gene mutations are found in approximately 30% of newly diagnosed acute myeloid leukemia (AML) patients; internal tandem duplication (ITD) mutations in the juxtamembrane domain of FLT3 account for two-thirds of FLT3 mutations. Patients with FLT3-ITD mutations have a poor prognosis, with shorter remission duration and higher relapse rates than FLT3 wild-type AML patients. Although several tyrosine kinase inhibitors (TKIs) targeting FLT3 improve clinical outcomes of FLT3-ITD-mutated AML, the median survival time of these patients is approximately 1  year.

Source: Leukemia Research - March 8, 2018 Category: Hematology Authors: Eun-Ji Choi, Je-Hwan Lee, Jung-Hee Lee, Han-Seung Park, Sun-Hye Ko, Eun-Hye Hur, Juhyun Moon, Bon-Kwan Goo, Yeonhee Kim, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Kyoo-Hyung Lee Tags: Research paper Source Type: research